Brief: Journal Of Thoracic Oncology Published Promising Results
30/10/2023 12:14
Oct 30 (Reuters) - Akeso Inc 9926.HK :
* JOURNAL OF THORACIC ONCOLOGY PUBLISHED PROMISING RESULTS
OF
IVONESCIMAB (PD-1/VEGF BISPECIFIC) AS FIRST- OR SECOND-LINE
THERAPY FOR ADVANCED OR METASTATIC IMMUNOTHERAPY NAÏVE
NON-SMALL-CELL LUNG CANCER
Source text for Eikon: ID:nPn6S1T9Ta
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals